Patent 10011653 was granted and assigned to Eli Lilly and Company on July, 2018 by the United States Patent and Trademark Office.
Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer's disease, Progressive Supranuclear Palsy and Pick's disease.